Kiarash Riazi
Overview
Explore the profile of Kiarash Riazi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riazi K, Ly M, Barty R, Callum J, Arnold D, Heddle N, et al.
Transfusion
. 2023 Oct;
63(12):2234-2247.
PMID: 37861272
Background: Managing Canada's immunoglobulin (Ig) product resource allocation is challenging due to increasing demand, high expenditure, and global shortages. Detection of groups with high utilization rates can help with resource...
2.
Harmon M, Riazi K, Callum J, Arnold D, Barty R, Sidhu D, et al.
Allergy Asthma Clin Immunol
. 2023 Sep;
19(1):85.
PMID: 37717038
Background: Canada has high immunoglobulin (IG) product utilization, raising concerns about appropriate utilization, cost and risk of shortages. Currently, there is no national set of standardized IG guidelines, and considerable...
3.
Newton J, Riazi K, Vashist N, Jarvis H, Lang E, Clement F, et al.
Intern Emerg Med
. 2023 Sep;
19(2):591-593.
PMID: 37658949
No abstract available.
4.
Riazi K, Swain M, Congly S, Kaplan G, Shaheen A
Nutrients
. 2022 Nov;
14(21).
PMID: 36364818
Non-alcoholic fatty liver disease (NAFLD) is a significant public health concern worldwide with a complex etiology attributed to behavioural, environmental, and genetic causes. The worldwide prevalence of NAFLD is estimated...
5.
Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E, et al.
Lancet Gastroenterol Hepatol
. 2022 Jul;
7(9):851-861.
PMID: 35798021
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and the leading cause of liver-related morbidity and mortality. We aimed to predict the burden of NAFLD...
6.
Shaheen A, Riazi K, Medellin A, Bhayana D, Kaplan G, Jiang J, et al.
CMAJ Open
. 2020 May;
8(2):E370-E376.
PMID: 32414883
Background: Identification of patients with nonalcoholic fatty liver disease (NAFLD) with advanced liver fibrosis in primary care remains an unmet need. Our primary objective was to implement a pathway driven...
7.
Riazi K, Raman M, Taylor L, Swain M, Shaheen A
Nutrients
. 2019 Nov;
11(12).
PMID: 31779112
Nonalcoholic fatty liver disease (NAFLD) is a rising epidemic worldwide and will be the leading cause of cirrhosis, hepatocellular carcinoma, and liver transplant within the next decade. NAFLD is considered...
8.
Bahremand T, Payandemehr P, Riazi K, Noorian A, Payandemehr B, Sharifzadeh M, et al.
Epilepsy Behav
. 2017 Dec;
78:142-148.
PMID: 29195160
Agmatine is an endogenous l-arginine metabolite with neuroprotective effects in the stress-response system. It exerts anticonvulsant effects against several seizure paradigms. Swim stress induces an anticonvulsant effect by activation of...
9.
Riazi K, Galic M, Kentner A, Reid A, Sharkey K, Pittman Q
J Neurosci
. 2015 Mar;
35(12):4942-52.
PMID: 25810524
Peripheral inflammatory diseases are often associated with behavioral comorbidities including anxiety, depression, and cognitive dysfunction, but the mechanism for these is not well understood. Changes in the neuronal and synaptic...
10.
DMello C, Riazi K, Le T, Stevens K, Wang A, McKay D, et al.
J Neurosci
. 2013 Sep;
33(37):14878-88.
PMID: 24027287
Sickness behaviors, such as fatigue, mood alterations, and cognitive dysfunction, which result from changes in central neurotransmission, are prevalent in systemic inflammatory diseases and greatly impact patient quality of life....